摘要
已知人类致病性冠状病毒可分为7种,即HCoV-229E、HCoV-OC43、HCoV-HKU1、HCoV-NL63、SARSCoV、MERS-CoV和SARS-CoV-2。其中,后3种冠状病毒分别引起的严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)以及正全球蔓延的新型冠状病毒肺炎(COVID-19)都严重威胁了人类生命健康和社会经济发展。尽管人们针对致病性冠状病毒的药物研发投入巨大,也取得了一些进展,但迄今为止仍没有批准上市的抗冠状病毒特效药。本文系统地总结了近20年来报道的具有代表性的抗冠状病毒活性化合物共146个,列举了这些活性化合物的潜在靶标蛋白共26个,涉及病毒感染与复制整个过程,并预测了部分抗病毒活性机制不清的化合物的靶标蛋白,以期能够为推动抗冠状病毒新药的快速研发提供有益的参考。
Human pathogenic coronaviruses can be divided into seven types,namely HCoV-229 E,HCoV-OC43,HCoV-HKU1,HCoV-NL63,SARS-CoV,MERS-CoV and SARS-CoV-2.Among them,Severe Acute Respiratory Syndrome(SARS),Middle East Respiratory Syndrome(MERS)and Corona Virus Disease 2019(COVID-19),which are caused by the last three coronaviruses respectively,are enormous threats that challenge human health and social and economic development.Despite the huge investment in drug development for pathogenic coronaviruses,there is no specifically effective anti-coronavirus drug approved so far.In this review we systematically summarize 146 representative anti-coronavirus active compounds reported in the past 20 years and list 26 potential target proteins involved in the process of viral infection and replication.In addition,we predict the target proteins of those active compounds with unclear antiviral activity mechanisms.We hope that the information will be useful to accelerate the development of new anti-coronavirus drugs.
作者
王晓宇
彭诚
杨延青
石禹龙
朱正诞
穆凯洁
李慧玉
徐志建
朱维良
WANG Xiao-yu;PENG Cheng;YANG Yan-qing;SHI Yu-long;ZHU Zheng-dan;MU Kai-jie;LI Hui-yu;XU Zhi-jian;ZHU Wei-liang(College of Mathematics and Physics,Shanghai University of Electric Power,Shanghai 200090,China;Drug Discovery and Design Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;School of Pharmacy,University of Chinese Academy of Sciences,Beijing 100049,China)
出处
《药学学报》
CAS
CSCD
北大核心
2020年第10期2340-2357,共18页
Acta Pharmaceutica Sinica
基金
国家重点研发计划课题(2016YFA0502301)。
